| Diabetic Retinopathy
Iluvien vs Cimerli
Side-by-side clinical, coverage, and cost comparison for diabetic retinopathy.Deep comparison between: Iluvien vs Cimerli with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCimerli has a higher rate of injection site reactions vs Iluvien based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cimerli but not Iluvien, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Iluvien
Cimerli
At A Glance
Intravitreal injection
Corticosteroid
Intravitreal injection
Monthly
VEGF-A antagonist
Indications
- Diabetic Retinopathy
- Uveitis
- Exudative age-related macular degeneration
- Retinal Vein Occlusion
- Macular edema due to diabetes mellitus
- Diabetic Retinopathy
- Myopic choroidal neovascularization
Dosing
Diabetic Retinopathy, Uveitis Single 0.19 mg (190 mcg) fluocinolone acetonide intravitreal implant injected under aseptic conditions via a preloaded single-use applicator; optimal placement is inferior to the optic disc and posterior to the equator, with needle entry 4 mm inferotemporal from the limbus.
Exudative age-related macular degeneration 0.5 mg (0.05 mL) by intravitreal injection once monthly (approximately 28 days); alternatively, 3 monthly doses followed by less frequent dosing, or one dose every 3 months after 4 monthly doses, with regular assessment.
Retinal Vein Occlusion 0.5 mg (0.05 mL) by intravitreal injection once monthly (approximately 28 days).
Macular edema due to diabetes mellitus, Diabetic Retinopathy 0.3 mg (0.05 mL) by intravitreal injection once monthly (approximately 28 days).
Myopic choroidal neovascularization 0.5 mg (0.05 mL) by intravitreal injection once monthly (approximately 28 days) for up to 3 months; may be retreated if needed.
Contraindications
- Active or suspected ocular or periocular infections, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases
- Glaucoma with cup to disc ratio greater than 0.8
- Known hypersensitivity to any components of ILUVIEN
- Ocular or periocular infections
- Known hypersensitivity to ranibizumab products or any excipient in CIMERLI
Adverse Reactions
Most common (>=1%) Cataract, increased intraocular pressure, myodesopsia, eye pain, conjunctival haemorrhage, posterior capsule opacification, eye irritation, vitreous detachment, conjunctivitis, corneal oedema, ocular hyperaemia, anemia, headache, renal failure, pneumonia
Serious Optic nerve damage, visual acuity and field defects, secondary ocular infections including herpes simplex, perforation of the globe where there is thinning of the cornea or sclera
Postmarketing Drug administration error, drug ineffectiveness
Most common Conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, vitreous detachment, cataract, nasopharyngitis, anemia, nausea, cough
Serious Endophthalmitis, retinal detachment, increased intraocular pressure, thromboembolic events, rhegmatogenous retinal detachment, iatrogenic traumatic cataract
Postmarketing Tear of retinal pigment epithelium (patients with neovascular AMD)
Pharmacology
Fluocinolone acetonide is a synthetic corticosteroid that inhibits inflammatory responses by blocking phospholipase A2 via lipocortins, suppressing biosynthesis of prostaglandins and leukotrienes and reducing edema, leukocyte migration, capillary proliferation, and fibroblast proliferation.
Ranibizumab-eqrn is a recombinant humanized IgG1 kappa monoclonal antibody fragment that binds to active forms of VEGF-A, preventing interaction with VEGFR1 and VEGFR2 on endothelial cells, thereby reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation in ocular conditions.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Iluvien
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
Cimerli
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Iluvien
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Cimerli
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Iluvien
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Cimerli
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25
Iluvien CoPay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: Macular Disease
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IluvienView full Iluvien profile
CimerliView full Cimerli profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.